Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; IDEC-C2B8 Study Group in Japan. Igarashi T, et al. Among authors: ohtsu t. Ann Oncol. 2002 Jun;13(6):928-43. doi: 10.1093/annonc/mdf155. Ann Oncol. 2002. PMID: 12123339 Free article. Clinical Trial.
Re-treatment of relapsed indolent B-cell lymphoma with rituximab.
Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K; IDEC-C2B8 Study Group. Igarashi T, et al. Among authors: ohtsu t. Int J Hematol. 2001 Feb;73(2):213-21. doi: 10.1007/BF02981940. Int J Hematol. 2001. PMID: 11372734 Clinical Trial.
Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K; Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG). Itoh K, et al. Among authors: ohtsu t. Ann Oncol. 2002 Sep;13(9):1347-55. doi: 10.1093/annonc/mdf287. Ann Oncol. 2002. PMID: 12196359 Free article. Clinical Trial.
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Midorikawa S, Ohtsu T, Tobinai K. Ogura M, et al. Among authors: ohtsu t. Lancet Haematol. 2016 Mar;3(3):e107-18. doi: 10.1016/S2352-3026(15)00284-7. Epub 2016 Feb 12. Lancet Haematol. 2016. PMID: 26947199 Clinical Trial.
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Ishida T, et al. Among authors: ohtsu t. J Clin Oncol. 2016 Dec;34(34):4086-4093. doi: 10.1200/JCO.2016.67.7732. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621400 Clinical Trial.
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, Ando K, Tsukasaki K, Ishida T, Kobayashi N, Ishizawa K, Tatsumi Y, Kato K, Kiguchi T, Ikezoe T, Laille E, Ro T, Tamakoshi H, Sakurai S, Ohtsu T. Maruyama D, et al. Among authors: ohtsu t. Int J Hematol. 2017 Nov;106(5):655-665. doi: 10.1007/s12185-017-2286-1. Epub 2017 Jun 29. Int J Hematol. 2017. PMID: 28664499 Clinical Trial.
[Pharmacodynamics of anticancer agents].
Ohtsu T, Sasaki Y. Ohtsu T, et al. Gan To Kagaku Ryoho. 1993 Sep;20(12):1741-9. Gan To Kagaku Ryoho. 1993. PMID: 8379667 Review. Japanese.
168 results